Rimonabant

Danger

H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]；H371 (50%): May cause damage to organs [Warning Specific target organ toxicity, single exposure]；H372 (50%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]；H373 (50%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]；H410 (50%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]

P203, P260, P264, P270, P273, P280, P308+P316, P318, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

A - Alimentary tract and metabolism；A08 - Antiobesity preparations, excl. diet products；A08A - Antiobesity preparations, excl. diet products；A08AX - Other antiobesity drugs；A08AX01 - Rimonabant

QA - Alimentary tract and metabolism；QA08 - Antiobesity preparations, excl. diet products；QA08A - Antiobesity preparations, excl. diet products；QA08AX - Other antiobesity drugs；QA08AX01 - Rimonabant

In the RIO-North America trial, 3040 patients were randomized to receive either placebo or one of two doses of rimonabant (5 mg or 20 mg per day). Patients taking 20 mg rimonabant had significant weigh loss, decrease in waist circumference, improved insulin sensitivity, and increases in HDL cholesterol, compared to patients on placebo.

Rimonabant is a specific CB1 cannabinoid receptor antagonist. There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders.

Agents that increase energy expenditure and weight loss by neural and metabolic regulation.

Compounds that inhibit or block the activity of CANNABINOID RECEPTORS.